BiotechTube

Part A: AZD8186 monotherapy + Part B: AZD8186 monotherapy + Part C1: Abiraterone acetate combination with AZD8186 + Part D1: AZD2014 combination with AZD8186 + Part D2 AZD2014 combination with AZD8186 + Part C2: Abiraterone acetate combination with AZD8186

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Castrate-resistant Prostate Cancer CRPC

Conditions

Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC

Trial Timeline

Jul 9, 2013 → Feb 7, 2020

NCT ID
NCT01884285

About Part A: AZD8186 monotherapy + Part B: AZD8186 monotherapy + Part C1: Abiraterone acetate combination with AZD8186 + Part D1: AZD2014 combination with AZD8186 + Part D2 AZD2014 combination with AZD8186 + Part C2: Abiraterone acetate combination with AZD8186

Part A: AZD8186 monotherapy + Part B: AZD8186 monotherapy + Part C1: Abiraterone acetate combination with AZD8186 + Part D1: AZD2014 combination with AZD8186 + Part D2 AZD2014 combination with AZD8186 + Part C2: Abiraterone acetate combination with AZD8186 is a phase 1 stage product being developed by AstraZeneca for Advanced Castrate-resistant Prostate Cancer CRPC. The current trial status is completed. This product is registered under clinical trial identifier NCT01884285. Target conditions include Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC.

What happened to similar drugs?

16 of 20 similar drugs in Advanced Castrate-resistant Prostate Cancer CRPC were approved

Approved (16) Terminated (1) Active (4)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅letrozoleJiangsu Hengrui MedicineApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅FulvestrantAstraZenecaApproved
✅Zoladex and CasodexAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Alpelisib + FulvestrantNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01884285Phase 1Completed

Competing Products

20 competing products in Advanced Castrate-resistant Prostate Cancer CRPC

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
AK-105AkesoPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
pegfilgrastim + LY2523355Eli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
BT1718Bicycle TherapeuticsPhase 1/2
22
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
IMC-18F1Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
26
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
24
LY3434172Eli LillyPhase 1
21